Answers are grounded in this paper and cite their sources.
High Resolution Image Download MS PowerPoint Slide The immune checkpoint protein B7–H3 (CD276) is overexpressed in various cancers and is an attractive target for the treatment of malignant tumors. Radionuclide molecular imaging of B7–H3 expression using engineered scaffold proteins such as Affibody molecules is a promising strategy for the selection of potential responders to B7–H3-targeted therapy. Feasibility of B7–H3 imaging was demonstrated using two 99m Tc-labeled probes, AC12 and an affinity-matured SYNT179 using a [ 99m Tc]Tc-GGGC label. This study aimed to evaluate whether the use of a residualizing 111 In-based label provides better imaging contrast compared with a nonresidualizing label. To do that, SYNT179 and AC12-GGGC Affibody molecules were labeled with 111 In using (4,10-bis-carboxymethyl-7-{[2-(2,5-dioxo-3-thioxo-pyrrolidin-1-yl)-ethylcarbamoyl]-methyl}-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid (maleimide-DOTA) chelator, site-specifically coupled to the C-terminus of Affibody molecules. The binding affinities of the 111 In-labeled conjugates to B7–H3-expressing living cells were higher compared with the affinities of the 99m Tc-labeled variants. In mice with B7–H3-expressing xenografts, the tumor uptake of 111 In-labeled proteins (3.6 ± 0.3 and 1.8 ± 0.5%ID/g for [ 111 In]In-SYNT179-DOTA and [ 111 In]In-AC12-DOTA, respectively) was significantly ( p < 0.05, ANOVA) higher than those for 99m Tc-labeled counterparts (1.6 ± 0.2%ID/g and 0.8 ± 0.2%ID/g for [ 99m Tc]Tc-SYNT179 and [ 99m Tc]Tc-AC12-GGGC, respectively). The best variant, [ 111 In]In-SYNT179-DOTA, provided a tumor-to-blood ratio of 31.1 ± 2.9, which was twice higher than that for [ 99m Tc]Tc-SYNT179 and 7-fold higher than that for [ 99m Tc]Tc-AC12-GGGC. Both 111 In-labeled Affibody molecules had higher renal retention compared with 99m Tc-labeled ones, but the hepatobiliary excretion of 111 In-labeled proteins was appreciably lower, potentially improving the imaging of abdominal metastases. Overall, [ 111 In]In-SYNT179-DOTA is the most promising tracer for visualization of B7–H3 expression.
No takes yet. Share an insight, caveat, or question.
Tolmachev et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: